![]() |
|
||
---|---|---|
hal-01389962v1
Journal articles
The bendamustine plus rituximab regimen is active against primary nodal marginal zone B-cell lymphoma: Bendamustine-rituximab in nodal MZL Hematological Oncology, Wiley, 2016, ⟨10.1002/hon.2334⟩ |
||
|